Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs
To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date betwee...
Gespeichert in:
| Veröffentlicht in: | Clinical diabetes 2021-04, Vol.39 (2), p.160-166 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 2 |
| container_start_page | 160 |
| container_title | Clinical diabetes |
| container_volume | 39 |
| creator | Fox, Bradley Q Benjamin, Peninah F Aqeel, Ammara Fitts, Emily Flynn, Spencer Levine, Brian Maslak, Elizaveta Milner, Rebecca L Ose, Benjamin Poeschla, Michael Ray, Meghna Serino, Maeve Shah, Sahaj S Close, Kelly L |
| description | To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from |
| doi_str_mv | 10.2337/cd20-0049 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8061554</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2528177809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3189-508471ec3de7344202c684bd759772f997cdff009717cde769a82f3bd553a4de3</originalsourceid><addsrcrecordid>eNpdkctKBDEQRYMoOj4W_oAE3OiiNc9OshFkfIKDCLoOmXR6jPYkmnQL_r0ZR0VdVRV1uNyqC8AuRkeEUnFsG4IqhJhaASOsGK-Y4nQVjJBUuJKKqA2wmfMTQogTItfBBqVK1rxWI3A3jqH3YYhDhpfdYGN2cBKD72PyYQYfyugDHHc-eGs6eJ-86TJsY4K3oZqY9Ox6eObN1PUuw7M0zPI2WGsL43a-6hZ4uDi_H19VN7eX1-PTm8pSLFXFkWQCO0sbJyhjBBFbSzZtBFdCkFYpYZu2RUgJXDonamUkaem04Zwa1ji6BU6Wui_DdO4a60KfTKdfkp-b9K6j8frvJvhHPYtvWqIac86KwMGXQIqvg8u9nvtsXdeZ4Mo7NOFEYiEkUgXd_4c-xSGFcl6hMMcU80_qcEnZFHNOrv0xg5FeBKUXQelFUIXd--3-h_xOhn4AJlyNXA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2515131509</pqid></control><display><type>article</type><title>Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Fox, Bradley Q ; Benjamin, Peninah F ; Aqeel, Ammara ; Fitts, Emily ; Flynn, Spencer ; Levine, Brian ; Maslak, Elizaveta ; Milner, Rebecca L ; Ose, Benjamin ; Poeschla, Michael ; Ray, Meghna ; Serino, Maeve ; Shah, Sahaj S ; Close, Kelly L</creator><creatorcontrib>Fox, Bradley Q ; Benjamin, Peninah F ; Aqeel, Ammara ; Fitts, Emily ; Flynn, Spencer ; Levine, Brian ; Maslak, Elizaveta ; Milner, Rebecca L ; Ose, Benjamin ; Poeschla, Michael ; Ray, Meghna ; Serino, Maeve ; Shah, Sahaj S ; Close, Kelly L</creatorcontrib><description>To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from <5% before 2005 to 12.5% in 2019. However, it is still low given its inclusion in the American Diabetes Association's latest guidelines and known limitations of A1C for assessing ongoing diabetes care.</description><identifier>ISSN: 0891-8929</identifier><identifier>EISSN: 1945-4953</identifier><identifier>DOI: 10.2337/cd20-0049</identifier><identifier>PMID: 33986569</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Clinical trials ; Diabetes ; Disease management ; Glucose monitoring ; Glycemic index ; Prescription drugs</subject><ispartof>Clinical diabetes, 2021-04, Vol.39 (2), p.160-166</ispartof><rights>2021 by the American Diabetes Association.</rights><rights>Copyright American Diabetes Association Apr 1, 2021</rights><rights>2021 by the American Diabetes Association 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3189-508471ec3de7344202c684bd759772f997cdff009717cde769a82f3bd553a4de3</citedby><cites>FETCH-LOGICAL-c3189-508471ec3de7344202c684bd759772f997cdff009717cde769a82f3bd553a4de3</cites><orcidid>0000-0002-3354-7657</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061554/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061554/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33986569$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fox, Bradley Q</creatorcontrib><creatorcontrib>Benjamin, Peninah F</creatorcontrib><creatorcontrib>Aqeel, Ammara</creatorcontrib><creatorcontrib>Fitts, Emily</creatorcontrib><creatorcontrib>Flynn, Spencer</creatorcontrib><creatorcontrib>Levine, Brian</creatorcontrib><creatorcontrib>Maslak, Elizaveta</creatorcontrib><creatorcontrib>Milner, Rebecca L</creatorcontrib><creatorcontrib>Ose, Benjamin</creatorcontrib><creatorcontrib>Poeschla, Michael</creatorcontrib><creatorcontrib>Ray, Meghna</creatorcontrib><creatorcontrib>Serino, Maeve</creatorcontrib><creatorcontrib>Shah, Sahaj S</creatorcontrib><creatorcontrib>Close, Kelly L</creatorcontrib><title>Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs</title><title>Clinical diabetes</title><addtitle>Clin Diabetes</addtitle><description>To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from <5% before 2005 to 12.5% in 2019. However, it is still low given its inclusion in the American Diabetes Association's latest guidelines and known limitations of A1C for assessing ongoing diabetes care.</description><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Disease management</subject><subject>Glucose monitoring</subject><subject>Glycemic index</subject><subject>Prescription drugs</subject><issn>0891-8929</issn><issn>1945-4953</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkctKBDEQRYMoOj4W_oAE3OiiNc9OshFkfIKDCLoOmXR6jPYkmnQL_r0ZR0VdVRV1uNyqC8AuRkeEUnFsG4IqhJhaASOsGK-Y4nQVjJBUuJKKqA2wmfMTQogTItfBBqVK1rxWI3A3jqH3YYhDhpfdYGN2cBKD72PyYQYfyugDHHc-eGs6eJ-86TJsY4K3oZqY9Ox6eObN1PUuw7M0zPI2WGsL43a-6hZ4uDi_H19VN7eX1-PTm8pSLFXFkWQCO0sbJyhjBBFbSzZtBFdCkFYpYZu2RUgJXDonamUkaem04Zwa1ji6BU6Wui_DdO4a60KfTKdfkp-b9K6j8frvJvhHPYtvWqIac86KwMGXQIqvg8u9nvtsXdeZ4Mo7NOFEYiEkUgXd_4c-xSGFcl6hMMcU80_qcEnZFHNOrv0xg5FeBKUXQelFUIXd--3-h_xOhn4AJlyNXA</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Fox, Bradley Q</creator><creator>Benjamin, Peninah F</creator><creator>Aqeel, Ammara</creator><creator>Fitts, Emily</creator><creator>Flynn, Spencer</creator><creator>Levine, Brian</creator><creator>Maslak, Elizaveta</creator><creator>Milner, Rebecca L</creator><creator>Ose, Benjamin</creator><creator>Poeschla, Michael</creator><creator>Ray, Meghna</creator><creator>Serino, Maeve</creator><creator>Shah, Sahaj S</creator><creator>Close, Kelly L</creator><general>American Diabetes Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3354-7657</orcidid></search><sort><creationdate>20210401</creationdate><title>Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs</title><author>Fox, Bradley Q ; Benjamin, Peninah F ; Aqeel, Ammara ; Fitts, Emily ; Flynn, Spencer ; Levine, Brian ; Maslak, Elizaveta ; Milner, Rebecca L ; Ose, Benjamin ; Poeschla, Michael ; Ray, Meghna ; Serino, Maeve ; Shah, Sahaj S ; Close, Kelly L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3189-508471ec3de7344202c684bd759772f997cdff009717cde769a82f3bd553a4de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Disease management</topic><topic>Glucose monitoring</topic><topic>Glycemic index</topic><topic>Prescription drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fox, Bradley Q</creatorcontrib><creatorcontrib>Benjamin, Peninah F</creatorcontrib><creatorcontrib>Aqeel, Ammara</creatorcontrib><creatorcontrib>Fitts, Emily</creatorcontrib><creatorcontrib>Flynn, Spencer</creatorcontrib><creatorcontrib>Levine, Brian</creatorcontrib><creatorcontrib>Maslak, Elizaveta</creatorcontrib><creatorcontrib>Milner, Rebecca L</creatorcontrib><creatorcontrib>Ose, Benjamin</creatorcontrib><creatorcontrib>Poeschla, Michael</creatorcontrib><creatorcontrib>Ray, Meghna</creatorcontrib><creatorcontrib>Serino, Maeve</creatorcontrib><creatorcontrib>Shah, Sahaj S</creatorcontrib><creatorcontrib>Close, Kelly L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fox, Bradley Q</au><au>Benjamin, Peninah F</au><au>Aqeel, Ammara</au><au>Fitts, Emily</au><au>Flynn, Spencer</au><au>Levine, Brian</au><au>Maslak, Elizaveta</au><au>Milner, Rebecca L</au><au>Ose, Benjamin</au><au>Poeschla, Michael</au><au>Ray, Meghna</au><au>Serino, Maeve</au><au>Shah, Sahaj S</au><au>Close, Kelly L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs</atitle><jtitle>Clinical diabetes</jtitle><addtitle>Clin Diabetes</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>39</volume><issue>2</issue><spage>160</spage><epage>166</epage><pages>160-166</pages><issn>0891-8929</issn><eissn>1945-4953</eissn><abstract>To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from <5% before 2005 to 12.5% in 2019. However, it is still low given its inclusion in the American Diabetes Association's latest guidelines and known limitations of A1C for assessing ongoing diabetes care.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>33986569</pmid><doi>10.2337/cd20-0049</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3354-7657</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-8929 |
| ispartof | Clinical diabetes, 2021-04, Vol.39 (2), p.160-166 |
| issn | 0891-8929 1945-4953 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8061554 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Clinical trials Diabetes Disease management Glucose monitoring Glycemic index Prescription drugs |
| title | Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A00%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20Glucose%20Monitoring%20Use%20in%20Clinical%20Trials%20for%20On-Market%20Diabetes%20Drugs&rft.jtitle=Clinical%20diabetes&rft.au=Fox,%20Bradley%20Q&rft.date=2021-04-01&rft.volume=39&rft.issue=2&rft.spage=160&rft.epage=166&rft.pages=160-166&rft.issn=0891-8929&rft.eissn=1945-4953&rft_id=info:doi/10.2337/cd20-0049&rft_dat=%3Cproquest_pubme%3E2528177809%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2515131509&rft_id=info:pmid/33986569&rfr_iscdi=true |